Click on disease type or trial status for more information
Clinical Trials
| TRIAL NAME | DISEASE TYPE | TRIAL STATUS |
|---|---|---|
| Phase 1b Study of SNS-595 in Acute Leukemias | Acute Hematologic Malignancies | Recruiting Complete |
| A Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of SNS-595 Injection in Patients 60 Years of Age or older with Previously Untreated Acute Myeloid Leukemia | Acute Myeliod Leukemia | Initiating |
| Phase 1b Study of SNS-595 in Combination with Cytarabine in Acute Leukemias | Acute Myeloid Leukemia | Recruiting |
| Phase 2 Study of SNS-595 in Patients with Platinum-Resistant Ovarian Cancer | Ovarian Cancer | Recruiting |
| Phase 1 Study of SNS-032 in Chronic Lymphocytic Leukemia and Multiple Myeloma | B-Cell Malignancies | Recruiting |
| Phase 1 Study of SNS-314 in Advanced Solid Tumors | Solid Malignancies | Recruiting |
Sunesis is developing three drugs for treatment of various types of cancers. Phase 1 studies are focused on an initial assessment of the safety of each investigational drug. Most of the patients who participate in our Phase 1 studies have received several different treatments before enrolling. Our Phase 2 programs are focused typically on a specific type of cancer and usually have more restrictions on the types and numbers of prior cancer treatments.
LEARN MORE
LEARN MORE
LEARN MORE
LEARN MORE
LEARN MORE
LEARN MORE
Sunesis is an innovative biopharmaceutical company focused on therapeutics for oncology and other unmet medical needs.
Get access to the latest news and information about Sunesis, or search our news archive.
Copyright © Sunesis Pharmaceuticals, Inc. 2007. All Rights Reserved.